Good morning and welcome. This is Keith Meister. I am the Chairman of Centimeters Life Sciences and I'm thrilled to be here with you today. I am joined by Eli Kasdan, the CEO of Centimeters Life and Eric Schad, the CEO of Semaphore. We are very excited today to announce a very exciting transaction, the combination of Centimeters Life Sciences and Semaphore.
As you guys know, my background, I'm a generalist investor you who has sort of an expertise in helping invest in public companies and helping serve as a director and managing them through change. You. I've been friends with Eli since childhood. We grew up together, been friends for life. I've been fortunate enough to be the 1st investor in his fund, Kasdan Capital, in 2012.
You. And over the last decade, he's compounded money at exceptionally high rates of returns with a real focus on the life sciences space. Eli and I were talking about opportunities to provide capital to help grow businesses in his space back in June, and we came together and had this vision that together we could be partners where 1 plus 1 was equal to you more than 2, leveraging my expertise in capital market and Eli's expertise in life sciences to form a SPAC to help a business you of scale $2,000,000,000 type business, enter the public markets and use the public markets as a partner to grow from a $2,000,000,000 business a $5,000,000,000 business to $10,000,000,000 business to $20,000,000,000 business. Our hope was to find a great entrepreneur who wanted to grow in the public markets rather than to Zelle, who had a vision, who was early in his vision and with sponsorship, with capital and with intellectual capital could help execute that plan. You.
We were fortunate enough to find Eric and the SUMR-four team. Eli and Eric have had a relationship for a long time. I'm going to turn it over to Eli, but you. Simply put, we launched our stack in September with a view of finding a wonderful entrepreneur with a wonderful business with a big dream and a big vision you that could be accelerated by our capital and our team's know how, and we think we found the perfect partner with Eric and the Sema4 team, and we're thrilled to share that with you today. You.
Before I turn it over to Eric to walk through the business, I thought it might be helpful for Eli from an industry perspective to articulate why Sema4 is the perfect partner for Centimeters Life Sciences. You, Gilat.
Thanks, Keith. Yes, and I share Keith's excitement in being able to do this with Eric and Sema-four team. You. I think in the vision of doing a SPAC, as Keith said, the idea was to bring together great investors in the SPAC, a large capital base you and Board members on the spec that really understood the space. You'll see that we have Sean George, CEO of Invitae, Nat Turner, Co Founder and CEO of Flatiron, Emily Laproust, CEO of Twist, bring together industry expertise, a lot of capital and a vision to go and find a life science business, whether in the diagnostic you.
Space in the data space or in the tool space or maybe beyond and sort of come in with this expertise in capital and help them accelerate growth. You. We're in an exciting time in history where the integration of genomic and clinical data can be leveraged to really change health outcomes. You. But to do so, you need a purpose built company like Sema4 and particularly you need expertise on how to understand that data, you.
Generate that data and integrate that data. And I think what before you hear the story, what you should appreciate is that you. Eric Schott, the CEO and Founder of Sema4 is the world's expert in this endeavor. He has probably the most genomic publications by a factor. Those publications are of the most frequently cited and impactful you.
And he has built a career that really tracks to all the stakeholders and necessary technologies in the space beginning with Roche and Merck and then moving to PacBio, one of the leading sequencing platforms. And then going to Mount Sinai and really learning and understanding how clinical data. That is the data generated from the medical health records and your medical history and medication selection, you. How to take and then within an integrated health system. So all those professional experiences with this deep expertise and sort of you.
Brilliant, if you will, on stringing it together. He then went out and hired hundreds of data scientists, but not just sort of people out of the tech world, but data scientists that understand biology and understand clinical data so that they can you. You know how to pull it in and then weave it together to drive true impactful insightful outcomes. And so this company not only is you. Driving towards a white space, an important and valuable white space in the field, but with the greatest sort of team, the heavyweight, you.
The dream team of people behind it with the capital and the expertise from the Board and I would say Eric's you. This is just a really unique opportunity, and we're super excited to be a part of it. And Eric will take you through it. You'll see the vision very quickly, I imagine. You and thank you for taking the time.
I'll hand it over to you, Eric.
Thanks, Eli and thanks, Keith. I'm Eric Schott, the CEO of Sema4 you and super excited to be here and to be able to present Semafor to you in this partnership with Centimeters Life Sciences. And you. Our whole vision is centered around how do we generate aggregate and compute on very large scale high dimensional longitudinal patient you. Health data, doing that in collaboration, partnership with patients and providers, all to deliver next generation you.
Informed insights to better diagnose and treat patients. And so hopefully you see from that vision that this really is just perfectly aligned with this you. Centimeters Life Sciences team and what they envision for this SPAC and where they wanted to target it. You. This effort spun out of Mount Sinai about 3.5 years ago back in June of 2017, where I you.
I had started effort at Mount Sinai as a math compute guy to come in, charter with to come in and help Mount Sinai transform you. And to a next generation information driven health system. Like how could we enable such a health system to deliver better guidance, better outcome you. To patients by better engaging complex information models that better inform on patient health. You.
So when I first landed at Mount Sinai, so I was excited to drop into a big health system and gain access to millions of patients worth of data you. And to start analyzing those data to understand how can we better characterize longitudinal patient journeys to provide better guidance, you. And when I started examining the data and how do you how do we you. How are patients being diagnosed with certain diseases? And what you're looking at here is just a plot of all the diabetes patients at in the Mount Sinai you.
Health system. So tens of thousands given along the rows and along the columns this time and you're looking at you. When were patients that system diagnosed with diabetes and what was interesting to me is it was as if the patients were you over a certain period of time and then the next day they had diabetes as if there was a switch that got flipped and they went from being okay to having a disease. And we know you. What I didn't see was a lot of the data that gets generated around patients being used to inform on that decision and not just a binary Choice, but in a more probabilistic way to assess risk of a patient sliding into a disease type state and resolving that.
You. So I was looking at the increasing amounts of data we can generate on patients from the molecular side, which includes you. DNA sequencing, RNA sequencing, the kind of genomic data that we're involved in generating around patients, all the clinical information that again, you. Thousands of features collected on patients over time and forming on their health in deep ways. And of course, the increasing amounts of data that can be collected around patients outside of the health system through wearable devices or through health related apps.
And when I started to integrate a model you. Those data to better assess patient risk in diagnosing disease states and resolution of disease states, especially as the density of the data got higher. You. What you could clearly see is you went from this what appeared to be a binary switch to a clear indication of patients sliding into the you. It was loud and clear that they were going to develop the disease long before they clinically manifested the disease.
And not only could you. You see them cascade into the disease state, but you could see their ability to resolve the disease given different treatments or participating in different therapy arms. You. So all came into focus for me about how do we leverage that kind of information and you. Coming up with better risk models and better diagnostic models and better therapy matching models to help physicians you.
Assess the patient journey long before they clinically manifest the disease. So the whole mission became how can we span this chasm between the practice of medicine, you. The standard of care and the ability to enable that standard of care to engage high dimensional large scale data you. And decision making tools to provide more clinically actionable guidance. Like how can we enable physicians to engage that information in a more meaningful real time way you.
Given the very rapid rate of growth of the information and the modeling around it. So how could we you. Make that more real time. So that's the platform that we built out at Mount Sinai and ultimately spun into Semaphore you. And it's a next generation information platform that's currently married to a genomics platform.
But the platform itself again is about aggregating you. High dimensional data around patients both generating data, but also leveraging what exists around the patient and the medical record you. Reflecting those data of sophisticated models to interpret patients' conditions and risks and then being able to communicate you. Those kinds of model driven insights to physicians in an easy digestible way. You.
And of course given the scale of data and the rate of information and knowledge growth, this platform we had to architect to be you. Very dynamic and adaptable to learn as we learned from the insights how accurate the models were, refining the models and so on. So it's you. An adaptive learning type system that has the ability to deliver insights in a variety of different applications. So for example, you.
Of the genomes worth of information we now obtain on patients, we can employ machine learning based models on this platform that integrates that genomes worth of information and can provide risk assessments across an entire spectrum of disease, not just in a targeted area like cancer, but across the disease spectrum, whether it's cardiovascular disease, Alzheimer's disease, inflammatory bowel disease, like the whole range of disease and wellness. You. In addition, the platform can deliver insights by integrating high dimensional data generated around cancer patients. So whether it's you. Clinical data, imaging data, the DNA sequencing data that's generated on cancer patients both from their tumor and their germ line, you.
A whole transcriptome data integrating all of those data together to better assess molecular subtypes of the patient's tumor you. And then provide for better matching to the most appropriate therapy or to the most appropriate clinical trial. You. But even with the molecular data side, we don't need molecular data to provide those most meaningful insights. We have deep expertise.
You. The platform has the capability to integrate all the high dimensional data that's in the EMR systems to abstract from physician notes, you. Structure those data, integrate them with the rest of the structured data, harmonize those data across health systems to provide a more meaningful scale data set. You. And then we build longitudinal patient journeys off of that information and to provide, for example, better risk assessment.
So you. For example, in our women's health programs, we have the ability to model all of the complications of pregnancies longitudinally as the patient progresses through the pregnancy journey. You. So think of complications like preeclampsia, preterm birth and perinatal depression and hemorrhage, all of them impacting a woman's ability to have a safe pregnancy. You.
For some of the models that we construct like the preeclampsia models, it delivers positive predictive value, ability to predict preeclampsia you. And pregnant women, that's 5 times the standard of care. And so just examples of when you're able to embrace all of the information, you. Apply the most appropriate modeling to that data, you can truly transform standard of care.
So I love that example because you. In many of these instances you hear about these stories that are really have huge potential, but the reality of that potential is still way out in the you. This is an example of using this data genomic and clinical with fivefold accuracy diagnose the likelihood you. And being able to repair and intervene ahead of the event. That's basically the future of medicine is you.
Medicine to date has been very reactionary and using this data and approach like Semaphores, we're going to get into preemptive medicine. You. And preemptive medicine not only delivers better outcomes, but lowers cost to the entire system. So this is the future of medicine and Eric is delivering it here today. You.
So today the application of that platform is spanning 3 different areas. We started in women's health, you. The first application of this platform where we have the most comprehensive expanded carrier screening genomic test solution in the market in addition to noninvasive prenatal testing, but also have again that you. The prenatal testing, but also have again that longitudinal individualized health course trajectory modeling that we do on the pregnancy journeys as well to deliver differentiated insights through the course of care of a pregnant women. So of the women's health program today, we're at a run rate of just over 200,000 next you.
Generation sequencing test a year. That business is on a run rate of over $200,000,000 in revenue a year and growing at about a 30% clip. You. But because there's nothing specific to the platform we developed with respect to health condition or disease condition, you. We last year spun up our oncology solutions as well as another application of the platform, which includes a comprehensive you.
Exome based heritable cancer testing genomic solution in addition to a whole exome and transcriptome somatic profiling you. And so that's also combined with a variety of insights tools that again enables physician you. And patient in addition to researchers to engage that information and insights in a more meaningful way to help guide standard of care and decision making along the patient's cancer journey. In addition to these two areas, we again the platform being very general, it can characterize disease with the integration of this information across the broad Spectrum of Disease. And because we're generating a genome's worth of information on patients, as I said a few slides ago on the insights that can come from you.
We can assess risk across the range of diseases by integrating the genomic and clinical data to better inform you across the broad range of disease and wellness. So this population health focus that we're partnering with health systems on to provide a more you. Systematic characterization of all patients is again one of the first examples of the broad utility of our platform versus the specific focus in women's health and Ecology. But the business we built is sound originally targeting on the women's health side. You.
So you can see we did just over $190,000,000 in revenue last year, the bulk of that on the women's health side. But as we spun up you. Our oncology comprehensive oncology solutions, we're seeing really good growth on the oncology side and you. In addition, pharma partnership side as a lot of the pharma partnerships are enabled by the cancer data that we generate. So roughly 8% you.
Our revenue in 2020 was non women's health and non COVID based revenues are really attributed to the oncology and pharma partnerships. You. And we see over the next 3 years, the biggest revenue growth drivers will be in the oncology pharma partnerships and what we call secondary insights you. Asides of the business, which are getting paid to interpret data that's already existing, where we have some relationships with health systems, where we're providing you. Clinically actionable insights of genomic data that's already existing.
So we're not generating the data, but we're the interpreters of that data and providing you. Clinically actionable guidance that goes into the medical record. And also we'll say, you can see this distinction you. Yes, go ahead, Keith.
Let me just interject and make one point here that as a public markets investor, I find like the most powerful. You said the business is sound. I think you're being very, very humble. Eric and team have created an amazing scale business that's doing in excess of $200,000,000 you of run rate revenue from majority 90 percent women's health genomic testing. But on top of that revenue, there's a business that's an amazing platform.
You. As this graph shows between 2020 2023, we leverage the platform to scale growth and we get growth on growth on growth. We get you. Revenue growth of 38%. We get margin growth as we grow in oncology and secondary insights and biopharma NIPS and Health System Partnerships, all things that line of sight exist on.
And as Eric walks through the deck, he'll talk about the biopharma partnerships and the health system partnerships, you, all of which are leveraging the existing platform that's been built. So our margins are lower today at 22% because we're investing you for the future. But as time passes, we have line of sight on growth at higher margin. You. And as we have more growth with more margin, what we think will happen is this will go from being priced at a 7x multiple of 2021 revenue you as a heavily, women's health genomic testing business to being valued as a information and data platform as Eric and Eli have walked through you.
And that 7 times multiple can expand and has the opportunity to be a double digit revenue multiple. And to me, that's the exciting story and public markets will probably bring that multiple expansion forward very, very quickly, especially as we use the capital that's been raised to help leverage the platform and accelerate the growth. At the end of the deck, Eli and Eric will go through some of the organic and inorganic opportunities. But I just think of the setup as the platform has been built, there's a lot of scale revenue you. And as Eric now leverages partnerships and grow, there's real opportunity for multiple expansion and margin enhancement and that's the piece that gets me most excited as a public markets expert.
You. There's precedent for that kind of multiple expansion in the space through transactions, through these kind of growth maneuvers. You. This is Keith's right to see it because it's happened before.
Perfect. And I think it brings to light that the real play here again is about the you. And the expansion of the platform across a variety of use cases. You. So I won't go into Keith already summarized on what we expect and having invested in this platform, which you.
Initially leads to a lower gross margin, but that's just because we're generating again genomes worth of information on the patients, integrating that with their you. And over time, that's going to start paying off for us as we increasingly partner around that information with pharma and patients you to learn more about disease and how to better target and new therapies and so on. But also deriving multiple you. Insights from data that we generate once, but can be repeatedly interpreted for different conditions. So as that increases over time, like the margins you.
Also increased the revenue mix changes, it's increasingly coming from these partnerships and repeated insights from the information. You. And that's why you see the revenue growth over the next few years. You'll see in particular these health system you. Directed expansion.
So these are offering these genomic test solutions into health systems, but it's a more coherent holistic play. This you. It's about how can we bring this platform as a holistic precision medicine solution into a health system where we're standardizing you. The genomics platform, so enabling them to apply broad interpretations across genomes worth of information you. Off a standardized, harmonized set of data as opposed to hundreds of vendors and then leveraging that data you in the context of the clinical health data to make better decisions, more accurate predictions around their patients.
So increasingly, you'll see this expansion of health system you. Driven revenue, which again is all about wiring this platform into health systems to provide those kinds of solutions. So the strategy again is, you. Sure. We can go out and sell these solutions to individual practices and physicians.
But by wiring you. As a platform into the health systems themselves, we'll accelerate our access to more and more patients and more and more data around those patients as we become information partner with those systems. The aim is to start with a smaller number of systems where we're really going to learn in partnership with the systems, how to wire in this platform, you. What are the things we can automate and just dropping this platform that's functional today into the system versus what has to be customized with the system? How do we need to integrate you.
The information we generate, the insights we produce with their EMR systems, how do we facilitate them with tools that complement their EMR system, but taking into account physician workflows and not overburdening physicians, but actually lessening the workflows as we enable better insights. So that's kind of the game you that we're going to be driving. And again, it's not just focused on cancer or women's health. This has utility across the life course of a patient. And what we you.
Today is a lot of focus on the oncology episodic event in the life you. And lots of companies now able to leverage the next gen sequencing technologies from the somatic profiling to germ you. And I'm thrilled to be here with you. And I'm thrilled to be here with you. And I'm thrilled to be here with you.
And I'm thrilled to be
here with you. And I'm you. But that's just one episode in the life course of a patient. There are lots of other things that happen to patients and different diseases, whether it's autoimmune or diabetes, cardiovascular. You.
The generalizability of our platform to focus in all these different areas and provide insight enables us to play in a space that very few are able to operate in today. You. So we're excited to be one to have the potential to fill that kind of white space and complement the high degree of activity we see in oncology.
You. I think it's worth calling out that this is an important slide because these are all diseases. What we see mostly in the space right now are people sort of you in cancer oncology or in sort of women's health. But there are huge markets, Mike, as it shows, autoimmune, diabetes, cardiovascular. You.
These are all disease states that molecular information and clinical data can start to resolve the way we've seen it on oncology. So this is the TAM here you. And punch line is the TAM is obviously enormous.
And that's a great to hear Eli talk to have a sponsor who you. Has such a depth in this space, but it's a great call out that diseases like autoimmune, cancer is not the only one that can benefit from a liquid biopsy or from genomic sequence you. For integrating that molecular data with the clinical record, autoimmune, all these areas and I'll call it autoimmune specifically. You. There are a variety of new biologics flooding into the autoimmune space.
Most patients do not respond to those you. Biologics, so there's a high non response rate. There's a high AE, I want to say. So there's a high lots of drugs flooding in. The majority of patients you.
There's a high adverse event rate and the physician, so they don't really know how to you. But what they do is they write it down in the physician notes. So the ability to extract from physician notes just like it's been done in cancer you. To identify the predictive features of what's going to identify a patient that will actually respond to better target those drugs, better assess response rates, reduce you. Adverse event, increased outcomes like that same opportunity exists in all these spaces.
You. So the platform itself is structured as depicted here is comprised of a data management layer. So again, this is all about you. Managing increasing scales of data, computing on those data, so that's the Insights Engine and delivering those insights, having an API sitting on top of that Insights Engine you. I can target those insights to a bunch of different applications.
This is what I think is critical to the story, which is you. There are companies out there with one side of the data equation where they have some patient data, MR data or maybe they have molecular data like a testing company. You. But it's no one has this purpose built platform, that brings all these data feeds you into one system that can then lever. I mean, this is what I mean by that white space.
Flatiron, which is something we were involved in, you. Had one side on the clinical data side, Foundation Medicine had the genomic side. The vision always was to bring those things together you. And Eric went out and inside the Mount Sinai just to basically purpose built this. So I think it's incredibly important.
And I think the exciting thing is and you'll hear more about is how you leverage that data you into multiple channels.
Yes. Thanks, Eli. Exactly. And it really is about the end goal of Sema4 being this you. Insights driven engine managing increasing amounts and complexity of data, deriving insights from those data you.
And being able to provide them in real time across a variety of applications, whether it's clinical reporting, clinical trials, clinical decision support, population health management, you. All of those applications will increasingly depend to deliver the best outcomes, engagement of the digital universe of data, not just narrow slices of data. You. Today, this platform is managing on the order of 20 to 30 petabytes. We have 10,000,000 patients of clinical record data and then you.
For a big proportion of those roughly 500,000 or so have a genomic, a comprehensive genomic information as well. You. And of course this continues to grow as we feel this platform, not just in partnership with health systems and by pulling data, increasing amounts of data in from the outside and the literature. But we do operate a high end genomics testing solution lab you. That currently is at a run rate of over 200,000 next generation sequencing tests a year and growing.
And of course, you. The ability to engage patients and their health journeys in providing this kind of data insight increasingly fuels our data management engine. You. But ultimately is about driving insights from that data and delivering those insights into the standard of care. So again, one of the things that differentiates Semaphore you from a more, say, traditional information centered company is our ability to take a platform and use it directly you and the engagement of patients through their standard of care journeys.
So because we're providing these comprehensive genomic you. Testing solutions, generating the data on the patients, interpreting those data, delivering clinical reports and other insights to physicians you through a variety of software tools that we provide and patient and physician portals or integrating the insights directly into the EMR you on behalf of the physician and patient. We're partnered. We're partnered with the patient. We're partnered with the physician to be able to deliver you.
These kinds of services and insights and because we're in this trusted context operating in the standard of care in a very information driven way, you. We have the ability to also consent very broadly the patients who onboard into our platform because we're scheduling the appointments for them. You. We're doing the pretest genetic counseling with them. We're doing post test counseling with them.
We're delivering the results to them, enabling them you. To take control of their information and to make it portable so they can share it with others. So we're in this trusted context where patients can you. At a very high rate, in fact in our women's health and oncology channels, patients are consenting at about an 85% rate and very broadly for us to you. Enable them to take control and manage health related information about them through any health system they've ever been part of, you.
But also enables us to recontact them and again provide additional insights. You. So what really enables this vision to be realized at Sema4 is our investment in 4 foundational pillars. You. The first is the state of the art genomic infrastructure.
And while many think that the genomic sequencing today is commoditized, that's not quite true. You. That is still next generation sequencing is the only technology known to humankind to move at a super Moore's Law speed. So super disruptive, you. Moving very fast, the science is not yet fully worked out.
New technologies continue to flood onto the scene. And so in order to keep pace with that clients to move at that super Moore's Law pace. It pays to have deep technical and informatics expertise you in this arena. So we maintain a very strong effort around the genomic infrastructure. And longer term, like whether we need to you.
Down the road as this information platform becomes the way we interpret information and provide insights. I don't see us necessarily having to you. We'll leverage what others are doing. But for today, we maintain a strong focus on that technology. Another pillar is the access and engagement with both patients and physicians.
Again, because we're providing the standard of care services in partnership with the physicians and the health systems, you. We have this ability to engage patients directly, consent them directly, provide them access with their information, act on their behalf to acquire information across health systems and to harmonize that data and provide it back to them, provide them insights. And again, they consent at a very high rate. So it's a special relation you that we are able to form with patients that enables the patient along their journey. Our ability to analyze you.
Clinical data, genomic data at deep levels and annotate those data, curate those data, harmonize those data across health systems, make them interoperable as a core expertise you within SemaCore. And again, I'll just call out the ability to go into identified patient data into the physician notes, abstract knowledge you. And information from that unstructured data, structure those data and then again integrate it with the other healthcare information. And that's not just in cancer, that again is across all disease you. And ultimately, it's the unique insights, the ability to compute on those data, build predictive models and apply those models in you.
So I'll drill down a little bit in each of these areas just so you get a sense of what those pillars are really founded on. You. So the first is the genomics platform. So again, our platform, what we refer to as Travera is based on a whole exome, you. Low pass whole genome framework that again enables us to adapt at the rate of learning.
So think again, next gen sequencing you. Moving at super Moore's Law speed, the amount of information being generated and insights from those data is growing exponentially. So you need a system that's capable of adapting you. At that rate of learning, we think an exome based and low pass whole genome based architecture is the right model. As the cost of sequencing continues to drop, we'll you.
The amount of whole genome sequencing data generated and ultimately everything we generate will be a whole genome. This information you. That we generate has the ability to inform across 6,000 or so conditions and diseases. So it's in a clinically actionable way. So it's you.
Very holistic, very comprehensive from delivering the most comprehensive carrier screening to heritable cancer, to pharmacogenomics, you. To more generalized common disease screening, what we call polygenic risk scoring, where you're integrating genomic level of data across the patient you to assess a broad range of risks across many different disease areas. So again, it's a platform that we're able to clinically report you. In real time, as information, as knowledge, as insights change, we can reinterpret that information. But again, it allows you.
System to adopt this kind of platform and harmonize it standardizes the data over the entire population. You. And so that has value to patients and physicians as we're able to link the information you. We generate off that platform with again the patient records from the health systems, combine it with the AI driven insights that we can you. And providing a range of, again, insights back to physicians and patients.
Again, whether it's this broad you. Interpretation of the genomic information for better risk assessment in cancers like in heritable cancers like breast and prostate where increasingly you. The germline information is being used to establish standard of care treatments when such patients at high risk get cancer. So very important component to be ahead of you. Or whether it's integrating that transcriptomic data in the context of network based models that we build you.
Across the different types of cancer to inform on molecular subtyping and therapy matching, treatment matching or clinical trial matching, like again, the ability to go very deep with those data to better in a more personalized precise way classify patients and assign them to the right treatment. You. The other value to patients is again this acting on their behalf, managing their information and you. Engaging them in a way that they can make use of the information generated on them. So as just one example, we have the Pregnancy Journey app you.
For patients on a pregnancy journey who again onboard into our platforms because they're getting expanded carrier screening testing or they're getting you. The non invasive prenatal testing or newborn screening or drug safety testing, whatever the test in that journey is, they consent and then they're provided you. The information we can aggregate on them through this app and it provides both context for the journey they're on. Again, since they're consented, you. They've consented us to go into the, their behalf into their medical record to pull information.
We can do that in real time so we can update them you on all information being collected on them, what it means for the current place they're at in the journey, help educate them, provide them insights into those data you in a way that's easy for them to digest, to really understand what's going on at this stage of their journey and also to provide guidance. You. And again, doing this in partnership with the physicians and health systems. So just a more holistic engagement.
So I think you. Two critical components that are flagged in this slide that I would just want to call out quickly. One is that there are others in the space attempting to do this, but no one you in the way Sema4 has integrated the patient, engaged with the patient and the physician and the health system. So this is in cooperation, you, not in sort of isolation of these incredibly important stakeholders. So we've you.
Integrated the stakeholders, they've reached out and connected with them and they follow these stakeholders through the life cycle of the patient. You. And that just creates a virtuous circle of data coming in, value coming out the other side, creating more interest in participation you. And it sort of just feeds itself in this virtuous cycle that just increases the value of the platform for Semafor and for the stakeholders.
You. And of course, once you have this platform, both the standardized genomic platform along with the information you. Platform to better engage the physician and patients around insights that's of high value to health systems because what they really want is again this platform that helps enable them to you. Deliver precision medicine across areas like cancer, women's health, population health screening and so on. So we become a partner with a health system them to deliver the standardized platform, standardized insights that integrate into their electronic medical records system, better characterization of patients.
You. And again, we're partnered at a deep level with the system to help leverage that information and access to patients to better understand disease. You. Our value proposition to health systems is exactly along the lines of what we've already delivered today to Mount Sinai. You.
So remember Mount Sinai had brought me in as a math comp guy to help enable them to better engage complex information you. To leverage that information and models built on that information to deliver better standard of care, better insights to patients, you. Partnering with the system to enable them to enter the future of precision medicine. That's where the origins of this platform came from. You.
Unlike the needs that we may get comped with kind of move into these systems, they get not so sticky deals with you. Access to data and then they run off and sell that data. That's not our aim with these health systems. Our aim is to partner very intimately, you. Deliver very holistic solutions by engaging the information these systems collect on patients, the type of information we generate you.
On a standardized genomic platform that really spans the spectrum of a disease from the cancer profiling to the woman's health, to the population health screening, to drug safety, you. That's the comprehensive solution. We've been able to embed within the Mount Sinai system and that will now seek with this additional capital to replicate across other systems. You. So just as an example of the kind of just give you one example of a system where we're providing you.
Again, a standardized platform, this population health screen where the system very progressive in their use of genomic information and wanting to apply you. Genomic health screening across the entire patient population to better assess risk of disease across a number of disease areas. So think you. Hypercholesterolemia for cardiovascular anxiety, depression, a lot of drug safety pharmacogenomics. So we can provide the standardized you.
Platform worth of data. And while we won't get paid enough for that type of test to recover the cost of generating the data, you. What it provides is now there's a base of data that exists on a patient that can then be used going forward to inform in different episodes of the you. So for example, 20% of those patients who are tested for the population health screening will be at reproductive health age and you. Qualify for expanded carrier screening, the data already exists.
That becomes a software query to provide clinically actionable guidance you. Off the carrier screening test to the OVs. 10% to 20% will be at high risk for cancer. So the heritable cancer test again can you derived from that GM's worth of information and provide those insights to the physician. And again, we get reimbursed for performing you.
What becomes largely a software query to provide that clinically actionable guidance. You. And once you have access to broader sets of patients, data around those patients and ability to recontact, especially in context of a health system that's of high value to pharma partners across the entire drug lifecycle spectrum you. From the raw discovery side to the development side to commercialization and just to demonstrate the utility our data and patient engagement is providing, you. Just highlighting a few of the pharma relationships we have, one of which is based on I think of a raw discovery research project to better understand you.
Disease conditions in patients by running larger scale clinical trials with deep molecular profiling in addition to profiling patients with devices, you. Integrating all of that information, building predictive models to help this pharma company identify the next generation of target for this disease. You. Other pharma collaboration involves using our whole exome transcriptome test across different types of cancer to better you. Molecularly stratify patients into subtypes and better understand the drugs that are being tested in clinical trials you.
For biomarkers to better match those molecular subtypes to the novel treatments coming out of the clinical trials. You. In addition, we can leverage the existing clinical genomic asset that continues to grow to help pharma partners you both identify more accurately patients that would qualify for enrollment into their trials as well as actively recruiting them into the trial. You. So all of this is the kind of growth we'll see in the pharma partnership business as the scales of data you.
I just want to call out one thing, which is the last four things you talked about. That's the power of a platform back to this sort of integrated platform story where you basically through the same virtuous cycle of collecting data and marrying it you and analyzing it. You then can deliver it back to multiple different stakeholders at different value economic terms, you, whether it's the patient or the health system or the pharma. And
in the
way you've built this thing, you. You are sharing value with each of these partners and everyone is incentivized to keep giving you more data and enriching the value of the platform. So I think that that's you. Just to sort of tie it in, that's really the power of having a true platform technology.
Yes, it's a great point, Eli. And I'll just say that you. It is a partnership with the health systems of patients and around the data that provides not just the fuel for semaphore to keep driving forward, you, but also to the health system. There's some of these pharma deals we have where 60% of the revenue being generated by the program we launched with you. Are going to the health systems to help carry out basically to pay for carrying out the study, paying for indirect costs and so on.
So the health systems are you. Happy to be partnered with us because we're helping them drive revenue in innovative ways back into the system, be at the cutting edge of medicine you. And research that we become again this trusted partner with the health system doing what's right for the patient. So it's really important and it also brings up you. Why we're excited to drive forward and going public through the CMLS back is the kind you.
Capital that can be raised in the public market and be brought to bear on our balance sheet will help us build out fill some of the gaps in the platform that we have you. That will help more efficiently drive our solutions into the health systems, both more efficiently drive them in and help with the uptake, you to make the uptake of those solutions more efficient and accelerated as well. So we have a whole range of activity already underway to identify what are the key you. Technologies or gaps that we may want to buy to pull in as opposed to develop ourselves. And so we're excited you.
Have the scale of capital we need to again move the platform up at a faster clip.
You. This slide that we just showed up shows the team. This is a mature organization. I'll let Eric walk through the team and some new additions that have been made you both at the management level and the Board level to help prepare the company for its debut as a public company. Eric?
Yes. So just to quickly highlight, we you. You have a very strong senior team that has gotten 7.4 to where we're at today and will continue to help us launch into the future. You. Of course, the new Board representation that will come from Centimeters Life Sciences.
We're looking forward to adding talent to the Board. You. We're also very excited to announce that we recently brought on Isaac Ro as our Chief Financial Officer. You. Isaac, as you may know, was a former CFO of Thrive and has a very long history on the analyst side covering this you.
Knows it very, very deeply, understands very well the mission of Semafor and what's needed for us to advance in ways I just talked about today. We have you. Guys like Jamie Kaufman, our President and Chief Operating Officer, who has a long history having built out the health services IT businesses at IBM and Dell, you. Knows how to build and operate at scale. Tony Prentiss, our Chief Product Officer, having a deep consumer base expertise, how do we better link?
You. It was very purposeful to bring somebody in who's more consumer facing versus health focused because we want to more seamlessly engage with patients, you, not just as part of a health system, but in a more general way. So the thinking is more tuned in there and so on. So just a really solid team, recently brought on William O, world renowned you. Medical oncologist, physician scientist, Tayeppu, again, will help us continue to scale our oncology efforts.
And we have Mike Pollini, you. Former CEO of Foundation and now investor in Semaphore. So we're just very excited again to keep driving forward and now in partnership with Keith and Eli.
Yes. And I would just say that we've made many investments in this space and at the end of the day, you need a strong platform, but you need amazing people. And Eric has amassed, in addition to this group of operators that are seasoned, 150 data scientists, you. World leaders on his board. We're going to bring some leaders to his board as well from our board.
And you're going to have the you. CEO and founder behind Foundation Medicine and the one behind Flatiron now sitting at the same table aligned in a way that had never aligned you. So you really just have this very unique situation of capital platform and talent coming together to tackle you. A really big opportunity that there is no one positioned like this company. And so Keith and I and Eric, I think you.
I couldn't be more excited to be now an investor in Semafor and helping them grow.
You. With this solid team and the proceeds that are going to come from this transaction, the aim is to continue to fill out our platform you. To accelerate uptake and adoption into health systems and beyond. Some of the more important components you. Of this platform center around a more complete portfolio test.
We think liquid biopsy in you. In particular therapy selection and MRD are very important components to offer more comprehensive precision medicine you. Oncology into health systems. Of course, we want to increase ASPs across all the cancer tests. So operating in MolDX states, you.
Running in partnerships with health systems, the clinical utility and value based studies that will aid in adoption and increase reimbursement. You. So that's kind of on the genomic testing platform front. On the information side, we aim to again continue to accelerate you. Our ability to integrate and harmonize data across health systems, kind of scale that platform along the commoditized front with companies that are you already at scale.
I want to continue developing those partnerships of course, so we can focus more deeply on where the science you. Still remains to be fleshed out, which is in abstracting from unstructured data. In addition, they're beefing up the software development, product design development teams to you. Be able to customize the integration of this platform into health systems and more customizable streamlined ways. You.
So on this slide, we have already a number of deals that we're looking at across the different domains I just talked about from you. Again, the liquid biopsy front, the information front and those are all well on their way and we hope to in fact have some of these you.
Yes, I think this is an exciting component of the strategy, which is to recognize that you. This is very much a platform and in the true sense of a platform, there's inorganic actions you can take you to expand the platform and increase the productivity of the engine, expand the TAM. That includes, as Eric said, you investing in technologies on the front end for improved detection or disease monitoring and on the back end for better data integration or expanding into other areas of the system ramp up. All those accelerate growth, you. And in the end, expand multiple, we saw this very clearly with Invikae and Archer where Invikae was in the women's health business you.
Growing like a weed, but really trying to accelerate and it's pushing to oncology and through the Archer transaction you. Not only got oncology business much further along, but also at the same time enable the decentralized model. So you. Those kind of 1 plus 1 equals more than 2 and in that process obviously the company has really benefited. And so those 1 plus 1 equals more than 2 kind of transactions.
You. There are a variety of them in the space, orphan companies, orphan technologies or even attractive growing companies that want to be part of the Semaphore platform. You. And Eric has a really good network in those and we do as well. And we think combined, we can really help stimulate this inorganic component of the strategy, which is you, an important piece in this space.
Let me maybe spend a second on that just in terms of going through the transaction terms you. And because I think it highlights how this transaction is being structured to help accelerate growth. So we see a lot of value as Sema Emerges from having been incubated and built inside of a health system like Mount Sinai with a very, very high cost of capital and then venture funding you from leading sponsors into a fully distributed public company. And just the way SemaForce has been purpose built to succeed in the industry, we've worked with Eric to try and construct this transaction you to be purpose built to accelerate the growth. So as you saw in our announcement today, we raised a $350,000,000 pipe.
The total sources of capital in the transaction approximately $793,000,000 $443,000,000 from the existing Centimeters Life's SPAC and $350,000,000 from new pipe investors. You. As the press release highlights, those type investors include some of the leading large mutual funds, some of the world's leading growth investors you and some of the world's leading dedicated long only long dedicated healthcare investors, several of whom are existing investors in Semaphore increasing their participation. So we have $793,000,000 of new capital, and the uses are, 1st and foremost, you to capitalize the company's balance sheet with $500,000,000 of net cash at closing. So if you spend any time with Eric and Eli and I've spent a lot over the last several months, you.
They're almost giddy thinking about the opportunities to invest that money in the business to grow both organically and inorganically. So there'll be a $500,000,000 net cash position at closing you. And the incremental proceeds approximately $335 ish million will be used to buy down existing investors. That was really driven by us and how we structured the transaction Jim with a real goal to do a win win transaction with Mount Sinai where they can still be a large strategic partner with 2 board seats in the pro form a company and a key partner, but you. So a 25 ish percent shareholder and not a 50% shareholder, which we think helps Sema4 succeed as a public company.
You. So the transaction announced today at a $2,000,000,000 valuation approximately represents approximately 7 times revenue. The transaction is expected to close you in the first half of twenty twenty one. And frankly, the longest timing element in that is completing the 2020 audit. You.
We expect to have that completed in March and immediately thereafter, file the proxy and expect to close the transaction in the first half of twenty twenty one. You. I hope you guys share the excitement that Eli and Eric and I have. You. So I'll conclude today just by thanking Eric, the entire Sema-four family, all the employees, the investors, the shareholders, Mount Sinai you for letting us come together and to join you in this journey.
And we're thrilled to help partner to accelerate the next leg of the journey. And you. We welcome all of you and look forward to following up appropriately as you have questions. We hope you've been intrigued by your first exposure to Semaphore, and we look forward to communicating with you frequently in the weeks, months, quarters and years to come. Thank you very much.